Biblio

Author Title Type [ Year(Asc)]
Filters: Author is June, Carl H  [Clear All Filters]
2024
Vittayawacharin P, Kongtim P, Chu Y, June CH, Bollard CM, Ciurea SO. Adoptive cellular therapy after hematopoietic stem cell transplantation. Am J Hematol. 2024.
2023
Wellhausen N, O'Connell RP, Lesch S, Engel NW, Rennels AK, Gonzales D, Herbst F, Young RM, K Garcia C, Weiner D, et al. Epitope base editing CD45 in hematopoietic cells enables universal blood cancer immune therapy. Sci Transl Med. 2023:eadi1145.
2022
Bai Z, Woodhouse S, Zhao Z, Arya R, Govek K, Kim D, Lundh S, Baysoy A, Sun H, Deng Y, et al. Single-cell antigen-specific landscape of CAR T infusion product identifies determinants of CD19-positive relapse in patients with ALL. Sci Adv. 2022;8(23):eabj2820.
2021
Qazilbash MH, Saini NY, Soung-Chul C, Wang Z, Stadtmauer E, Baladandayuthapani V, Lin H, Tross B, Honhar M, Rao SS, et al. A Randomized Phase II Trial of Idiotype Vaccination and Adoptive Autologous T-Cell Transfer in Multiple Myeloma patients. Blood. 2021.
2020
He X, Feng Z, Ma J, Ling S, Cao Y, Gurung B, Wu Y, Katona BW, O'Dwyer KPatrick, Siegel DL, et al. Bi-specific and Split CAR T Cells Targeting CD13 and TIM3 Eradicate Acute Myeloid Leukemia. Blood. 2020.
Parker KR, Migliorini D, Perkey E, Yost KE, Bhaduri A, Bagga P, Haris M, Wilson NE, Liu F, Gabunia K, et al. Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies. Cell. 2020.
2015
Garfall AL, Maus MV, Hwang W-T, Lacey SF, Mahnke YD, J Melenhorst J, Zheng Z, Vogl DT, Cohen AD, Weiss BM, et al. Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma. N Engl J Med. 2015;373(11):1040-1047.
Fowler DH, Mossoba ME, Halverson DC, Kurlander R, Schuver BBlacklock, Carpenter AE, Hansen B, Steinberg SM, Ali SAbbas, Tageja N, et al. High-Dose Sirolimus And Immune Selective Pentostatin Plus Cyclophosphamide Conditioning Yields Stable Mixed Chimerism and Insufficient Graft-Versus-Tumor Responses. Clin Cancer Res. 2015.
Rapoport AP, Stadtmauer EA, Binder-Scholl GK, Goloubeva O, Vogl DT, Lacey SF, Badros AZ, Garfall A, Weiss B, Finklestein J, et al. NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. Nat Med. 2015.
2014
Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, et al. Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia. N Engl J Med. 2014;371(16):1507-1517.
Rapoport AP, Aqui NA, Stadtmauer EA, Vogl DT, Xu YYan, Kalos M, Cai L, Bin Fang H-, Weiss BM, Badros A, et al. Combination Immunotherapy after ASCT for Multiple Myeloma Using MAGE-A3/Poly-ICLC Immunizations Followed by Adoptive Transfer of Vaccine-Primed and Costimulated Autologous T Cells. Clin Cancer Res. 2014.